Source link : https://www.newshealth.biz/health-news/new-agent-for-biliary-tract-cancer-approved/
The U.S. Food and Drug Administration (FDA) has approved zanidatamab (Ziihera, Jazz Pharmaceuticals, Inc.) as monotherapy for previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). This approval makes the bispecific antibody the first HER2-targeted treatment to carry the indication. Zanidatamab binds two separate regions on the HER2 cell surface protein, crosslinking neighboring HER2 […]
Author : News Health
Publish date : 2024-11-21 19:22:08
Copyright for syndicated content belongs to the linked Source.
Categories